Alkem Laboratories Limited

ALKEMNSE

Market snapshot · 2026-08-11 15:42 UTC

₹5,527.50

₹-71.00 (-1.27%)

MARKET CAP

₹66.09K Cr

STOCK P/E

28.7x

52W HIGH

₹5,933.50

52W LOW

₹4,822.00

BOOK VALUE

₹1,155.87

EPS

₹192.59

ROE

17.56%

SECTOR

Health Care

DEBT/EQUITY

14.27

VOLUME

1.16L

P/B RATIO

4.78x

PEG RATIO

-1.26

Sector

Health Care

Themes

PharmaceuticalsLife Insurance Corporation of India Portfolio

Dividend

Earnings

AI Summary

✦ Clartha

Price Forecast

Current

₹5,528

High Target

₹6,890

▲ +24.6%

Median Target

₹6,118

▲ +10.7%

Low Target

₹4,200

▼ -24.0%

Price history (1Y)

Analyst target range

20 analysts

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange (₹)Probability

3M₹4,876 - ₹6,49580%

6M₹4,678 - ₹7,01680%

12M₹4,458 - ₹7,90980%

Realized vol: +22.4% · Drift: +9.7%

Revenue Forecast

₹ Cr

Mar '26Current₹2,258.0

Sep 2026 ETrend estimate range

High₹2,995.0Base₹2,773.1Low₹2,551.3

PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share

Mar '26Current₹18.15

Sep 2026 ETrend estimate range

High₹68.09Base₹60.80Low₹53.50

PastCurrentTrend estimate: Low / Base / High

Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook

Neutral

59%

Analyst Consensus

Weakening

From 20 analysts

Mean upside+7.9%

Fundamentals

Moderate

Fundamentals institutional score is 63 using EVA spread proxy 5.6%; growth durability 33.6.

Valuation

Premium valuation

Valuation institutional score is 34 using relative multiple z-scores where peer dispersion is available.

Analyst Consensus

Neutral

Analyst View institutional score is 47 using mean target upside 7.9%; dispersion penalty 18.0; recommendation breadth from available consensus.

Technical Structure

Strong Trend

Technicals institutional score is 80 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Positive catalysts emerging

Recent news flow is balanced or not decisive enough to tilt the tape. Based on 8 recent ticker-linked news items.

Signal Summary

Market intelligence remains Neutral. technical structure and market sentiment provide support, while valuation and analyst consensus remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals ModerateValuation Premium valuationAnalyst Consensus NeutralTechnical Structure Strong TrendMarket Sentiment Positive catalysts emerging

Key Data Points

Mean Target Price5,964.8 target

Mean Upside+7.9%

Technical Score80%

Fundamental Score63%

Data CoverageHigh

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Trading 5.6% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +0.72). Confidence: 88%.

Live forward EPS implies next-12-month EPS of ₹226.20. Applying the stock's normalized valuation corridor produces a fair range of ₹5,668.57 to ₹6,458.01, with base value near ₹6,148.12 (+11.2% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Below normalized range

Forward EPS

₹226.20

Forward P/E

24.4x

Base Fair Value

₹6,148.12

Fair Range

₹5,668.57 - ₹6,458.01

Upside To Base

+11.2%

Estimate Source

Live forward EPS

Growth Estimate

-22.7%

P/E

5Y Average

22.79

Current

28.70

Overvalued

28.55

Undervalued

25.06

EV/EBITDA

5Y Average

17.85

Current

22.48

Overvalued

21.86

Undervalued

13.82

P/S

5Y Average

3.57

Current

4.49

Overvalued

4.10

Undervalued

3.03

Peers & Comparison

Sector: Health Care · Theme: Pharmaceuticals

Pharmaceuticals Peers8 peers

Avg P/E: 35.3x

Company	Rev. Growth	Margin	P/E	vs Avg	52W Perf.
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals	-5.6%	10.0%	30.7x Fair	-13% vs avg	-5.0%
HERO MOTOCORP LIMITED HEROMOTOCOTwo Wheelers	+34.9%	10.7%	21.1x Undervalued	-40% vs avg	+26.2%
CIPLA LTD CIPLAPharmaceuticals	+3.5%	12.0%	35.1x Fair	-1% vs avg	-3.8%
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres	+18.1%	7.7%	65.0x Premium	+84% vs avg	+23.2%
HINDALCO INDUSTRIES LTD HINDALCOMetals - Aluminium	+32.1%	5.5%	14.3x Undervalued	-59% vs avg	+58.0%
BAJAJ AUTO LIMITED BAJAJ-AUTOTwo Wheelers	+64.0%	16.3%	27.8x Undervalued	-21% vs avg	+42.5%
EICHER MOTORS LTD EICHERMOTTrucks & Buses	+31.5%	23.2%	38.1x Fair	+8% vs avg	+41.7%
BSE LIMITED BSEStock Exchanges & Ratings	+64.0%	48.9%	50.4x Premium	+43% vs avg	+50.1%

WHY THESE PEERS

ALKEM LABORATORIES LTD. trades at a discount (28.8x vs peer avg 35.3x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include DR. REDDY S LABORATORIES, HERO MOTOCORP LIMITED, CIPLA LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹2.26K CrMar 2026

Latest net profit

₹217 CrMar 2026

Latest EPS

₹18.15Mar 2026

Net margin

15.0%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %

Revenue
Net income
Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share

Revenue
EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore

Annual view

Debt
Free cash flow
Cash & equivalents

Results

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	2,238	2,253	2,635	2,009	2,365	2,127	2,355	2,287	2,045	2,372	2,542	2,491	2,258
Expenses +	1,906	1,919	1,980	1,517	1,958	1,566	1,714	1,629	1,748	1,752	1,771	1,802	1,914
Operating Profit	332	334	655	492	408	561	640	658	297	620	771	689	344
OPM %	15%	15%	25%	25%	17%	26%	27%	29%	15%	26%	30%	28%	15%
Other Income +	77	65	62	93	71	144	176	216	163	165	164	93	86
Interest	22	21	19	21	21	21	17	21	17	13	13	16	16
Depreciation	57	58	59	57	69	63	61	68	92	59	59	61	78
Profit before tax	330	319	639	508	389	621	738	785	351	714	864	706	336
Tax %	23%	15%	-1%	1%	16%	6%	5%	8%	21%	8%	9%	12%	35%
Net Profit +	255	271	647	504	325	583	698	723	277	656	787	622	217
EPS in Rs	21.31	22.70	54.07	42.17	27.18	48.78	58.34	60.48	23.16	54.88	65.80	52.03	18.15
Raw PDF
YOY Sales Growth %	11.55%	9.46%	7.03%	-12.53%	5.69%	-5.60%	-10.62%	13.84%	-13.55%	11.53%	7.95%	8.94%	10.44%
Material Cost %	41.95%	38.67%	37.96%	34.00%	39.37%	30.30%	31.77%	31.74%	35.39%	29.79%	27.06%	28.75%	30.98%
Employee Cost %	15.48%	18.38%	15.00%	19.17%	14.52%	18.84%	17.36%	18.30%	19.64%	19.80%	18.13%	19.49%	20.67%
Exceptional items	0	0	0	-2	-13	38	56	47	51	48	63	-38	-119
Other income normal	77	65	62	96	84	106	120	169	112	117	101	132	206
Exceptional items AT	0	0	0	5	-10	38	56	47	51	46	63	-31	-77
Profit excl Excep	255	271	647	499	335	546	642	676	226	610	724	654	294
Profit for PE	255	271	647	499	335	546	642	676	226	610	724	654	294
Profit for EPS	255	271	647	504	325	583	698	723	277	656	787	622	217
YOY Profit Growth %	231%	94%	84%	28%	31%	101%	-1%	35%	-33%	12%	13%	-3%	30%

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

Holder	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters +	53.04%	51.20%	51.20%	51.20%	49.70%
FIIs +	9.11%	9.47%	9.97%	10.15%	10.42%
DIIs +	21.80%	21.93%	21.54%	21.39%	22.64%
Public +	16.05%	17.39%	17.30%	17.25%	17.25%
Others	—	0.01%	—	0.01%	—

Jun 2026

Promoters +

FIIs +

DIIs +

Public +

Events Timeline

Annual Report FY26

FY2026PDFCompany Reports Open

Update On US FDA Inspection At Company'S Manufacturing Facility Located At Amaliya, Daman